Teva launches generic Actos

Brand Actos to improve blood sugar control in adults with type 2 diabetes has annual sales of $2.7 billion in the US.

On Friday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) launched generic versions of Actos and ACTOplus met, used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Brand Actos had annual sales of $2.7 billion in the US and ACTOplus met has $413 million in annual sales, based on IMS sales data. Both products are made by made by Japan's Takeda Pharmaceuticals Ltd. (TSE: 4502).

Teva did not obtain marketing exclusivity. Mylan Inc. (NYSE: MYL) and India's Ranbaxy Laboratories Ltd. (BSE: 500359). Watson Pharmaceuticals Inc. (NYSE: WPI) also plans to market generic Actos, and are waiting for US Food and Drug Administration (FDA) approval. The company also asked for 180 days marketing exclusivity.

Published by Globes [online], Israel business news - www.globes-online.com - on August 19, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017